SYN X Pharma Inc. Appoints Director of Regulatory Affairs

Apr 02, 2001, 01:00 ET from SYN X Pharma Inc.

    TORONTO, April 2 /PRNewswire/ - SYN X Pharma Inc. (CDNX: "SYY") today
 announced that Ms. Allison Manners has joined the company as Director,
 Regulatory Affairs. Ms. Manners comes to SYN X Pharma from Hemosol Inc. where
 she most recently held the positions of Manager, Global Regulatory Affairs and
 Quality Control. In those roles she was responsible for the regulatory
 processes necessary to conduct clinical trials. Ms. Manners has experience
 with filing and supporting the investigational new drug (IND) and clinical
 trial exemption (CTX) applications in Canada, the U.S. and in the European
 Union through all phases in the process. She led the regulatory approval
 process for Hemosol's lead product Hemolink(TM), which has been submitted to
 both the European Union and Canada for regulatory approval and was granted
 priority review status in this country.
     "Timely commercialization of products, derived from our Proteomics
 Discovery Platform(TM), is key to our future growth," said Sean McNicholas,
 President and Chief Executive Officer. "We continue to build the expertise of
 our team so that we can bring our products to market without delay."
     Ms. Manners will be responsible for all regulatory functions in Canada,
 the U.S. and all other markets. She will work closely with internal project
 teams, ensuring the adequacy of scientific information supporting product
 approval. Ms. Manners will also be responsible for implementing and managing
 strategies for development, registration and manufacture of all products,
 determining whether they meet applicable regulatory requirements and support
 business objectives for market access and reimbursement.
     SYN X Pharma Inc., (www.synxpharma.com), is a proteomics-based research
 and development company that capitalizes on its unique Proteomics Discovery
 Platform(TM) to identify protein targets for the development of new drugs and
 to deliver highly specialized antibody-based diagnostics.
     SYN X is currently developing several innovative diagnostics for
 diabetes, cardiovascular diseases that include heart failure and hypertension,
 and central nervous system diseases such as Alzheimer's Disease.
     SYN X Pharma Inc. has 5,438,360 common shares outstanding. The Canadian
 Venture Exchange has not reviewed and does not accept responsibility for the
 adequacy or accuracy of this release.
 
 

SOURCE SYN X Pharma Inc.
    TORONTO, April 2 /PRNewswire/ - SYN X Pharma Inc. (CDNX: "SYY") today
 announced that Ms. Allison Manners has joined the company as Director,
 Regulatory Affairs. Ms. Manners comes to SYN X Pharma from Hemosol Inc. where
 she most recently held the positions of Manager, Global Regulatory Affairs and
 Quality Control. In those roles she was responsible for the regulatory
 processes necessary to conduct clinical trials. Ms. Manners has experience
 with filing and supporting the investigational new drug (IND) and clinical
 trial exemption (CTX) applications in Canada, the U.S. and in the European
 Union through all phases in the process. She led the regulatory approval
 process for Hemosol's lead product Hemolink(TM), which has been submitted to
 both the European Union and Canada for regulatory approval and was granted
 priority review status in this country.
     "Timely commercialization of products, derived from our Proteomics
 Discovery Platform(TM), is key to our future growth," said Sean McNicholas,
 President and Chief Executive Officer. "We continue to build the expertise of
 our team so that we can bring our products to market without delay."
     Ms. Manners will be responsible for all regulatory functions in Canada,
 the U.S. and all other markets. She will work closely with internal project
 teams, ensuring the adequacy of scientific information supporting product
 approval. Ms. Manners will also be responsible for implementing and managing
 strategies for development, registration and manufacture of all products,
 determining whether they meet applicable regulatory requirements and support
 business objectives for market access and reimbursement.
     SYN X Pharma Inc., (www.synxpharma.com), is a proteomics-based research
 and development company that capitalizes on its unique Proteomics Discovery
 Platform(TM) to identify protein targets for the development of new drugs and
 to deliver highly specialized antibody-based diagnostics.
     SYN X is currently developing several innovative diagnostics for
 diabetes, cardiovascular diseases that include heart failure and hypertension,
 and central nervous system diseases such as Alzheimer's Disease.
     SYN X Pharma Inc. has 5,438,360 common shares outstanding. The Canadian
 Venture Exchange has not reviewed and does not accept responsibility for the
 adequacy or accuracy of this release.
 
 SOURCE SYN X Pharma Inc.